Adverse events occurring in ≥5% of patients aged 1-11 treated with
DUPIXENT and greater than placebo through 16 weeks2
DUPIXENT and greater than placebo through 16 weeks2
The safety profile of DUPIXENT through Week 16 of the EoE KIDS clinical study was
generally similar to the safety profile in adult and pediatric patients 12 years of age
and older with EoE. In Part B, a helminth infection was reported in one DUPIXENT-
treated subject.1
IMPORTANT ATTRIBUTES AND CONSIDERATIONS FOR DUPIXENT1
NO BOXED WARNING
Please see additional Warnings and Precautions
in the Prescribing Information and Important Safety
Information below.
NO KNOWN DRUG-TO-DRUG
INTERACTIONS
- Not metabolized through the liver or excreted through the kidneys
DUPIXENT IS NOT AN IMMUNOSUPPRESSANT
NO REQUIREMENT FOR INITIAL LAB
TESTING OR ONGOING LAB MONITORING,
according to the Prescribing Information
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme, have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.
Dosage and administration
Thinking about prescribing DUPIXENT? Find the information you need to get started.